They seem to be further along than the other compa
Post# of 72445
(Total Views: 419)
Posted On: 04/20/2020 11:14:38 AM
They seem to be further along than the other company. Having something already approved means that their delivery system has been found to be safe and effective, so it would be MUCH quicker to approval.
The advantage of Brilacidin in the IV form is that it reaches EVERY organ -- including kidney, heart, and brain, all of which appear to be affected by the COVID virus. You probably read about the Broadway star who had to have a leg amputated because of blood clots -- another common problem with COVID -- and Brilacidin's anti-inflammatory effects ought to help with that also.
But that's why for THIS disease, IV is better. It would reach everywhere, even other organs that may be affected that we haven't had enough experience with the disease to know about yet.
It would be great if there is an inhaled form that helps other diseases, like asthma and regular, non-COVID pneumonia -- but right now, IV is the best bet to help people quickly. And, since Brilacidin has already been through a Phase 2 clinical trial on THAT form, it would be much faster getting to approval.
The advantage of Brilacidin in the IV form is that it reaches EVERY organ -- including kidney, heart, and brain, all of which appear to be affected by the COVID virus. You probably read about the Broadway star who had to have a leg amputated because of blood clots -- another common problem with COVID -- and Brilacidin's anti-inflammatory effects ought to help with that also.
But that's why for THIS disease, IV is better. It would reach everywhere, even other organs that may be affected that we haven't had enough experience with the disease to know about yet.
It would be great if there is an inhaled form that helps other diseases, like asthma and regular, non-COVID pneumonia -- but right now, IV is the best bet to help people quickly. And, since Brilacidin has already been through a Phase 2 clinical trial on THAT form, it would be much faster getting to approval.
(14)
(0)